The FDA’s Peripheral and Central Nervous System Drugs advisory committee will discuss the merits of Biogen and Ionis’s ALS candidate tofersen on March 22nd.
https://www.pharmalive.com/wp-content/uploads/2022/05/US-Bridging-Study-Not-Enough-as-FDA-Denies-Hutchmeds-Pancreatic-Cancer-Drug-BioSpace-5-2-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-01-24 09:34:202023-01-24 09:36:33Neurofilament biomarker to face key test at Biogen-Ionis’ Tofersen Adcomm
